Regulation of the nucleotide state of oncogenic ras proteins by nucleoside diphosphate kinase

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Oncogenic Ras proteins, frequently mutated in cancers, display impaired GTPase activity, hindering their inactivation.
• Current therapeutic strategies lack effective methods to restore GTPase activity in mutant Ras proteins.
• GTPase activating proteins (GAPs) normally stimulate Ras inactivation, but oncogenic mutants are unresponsive.

Purpose of the Study:

• To identify factors capable of restoring GTPase activity to oncogenic Ras mutants.
• To explore potential therapeutic strategies for selectively inactivating mutant Ras proteins.
• To investigate the biochemical properties of K-Ras mutants and regulatory activities.

Main Methods:

• Characterization of biochemical properties of K-Ras mutants.
• Purification of an unknown activity from bacterial cell extracts.
• Identification of the purified protein responsible for Ras inactivation.
• In vitro biochemical assays to confirm the activity of the identified protein.

Main Results:

• An unexpected activity in bacterial extracts was found to stimulate the inactivation of the oncogenic K-RasG13D mutant.
• The protein responsible for this activity was purified and identified as nucleoside diphosphate kinase (NDK).
• NDK, closely related to the human metastasis suppressor NM23, was shown to convert active, GTP-bound Ras to inactive, GDP-bound Ras in vitro.
• These findings suggest a potential mechanism for the selective biochemical inactivation of oncogenic Ras.

Conclusions:

• Nucleoside diphosphate kinase (NDK) can biochemically inactivate oncogenic K-RasG13D in vitro.
• The discovery of NDK's activity provides a basis for developing novel therapeutic strategies targeting Ras-driven cancers.
• Further research into NDK's role in Ras regulation may elucidate its physiological relevance and therapeutic potential.